Scoping review highlights transparency gaps in economic studies of haemophilia, suggesting a need for better cost frameworks.
There were notable gaps, including inadequate reporting of model characteristics and input parameters, along with omission and mislabelling of cost categories. The findings underscore the urgent need for a disease-specific, standardised framework for societal cost categories and globally accessible costing datasets to enhance the consistency and transparency of economic studies in haemophilia.
No takes yet. Share an insight, caveat, or question.
El-Sayed et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: